Lowenthal Richard E

CEO Lowenthal sells 50,000 shares at $14.49; stock down 26.4% from 52-week high and -25.0% in 30 days

Richard E Lowenthal, President and CEO of ARS Pharmaceuticals, sold 50,000 shares (50.0K shares) at $14.49 on 2025-08-21, reducing his holdings from 1,246,494 shares to 1,196,494 shares. The transaction occurs amid sharp downward momentum: the stock is currently -26.4% from its 52-week high of $18.35 and has declined -25.0% over the past 30 days and -9.9% over 90 days. Lowenthal's prior five trades at SPRY have all been well-timed at the 90-day mark (5 of 5 prior sells were followed by declines), suggesting a pattern of selling before weakness; his cross-ticker track record shows a 90.00% well-timed rate on 20 prior sells with an average 90d return of -15.0%. The company's financials show a net loss of $44,883,000.00 against revenue of $15,717,000.00 (latest quarter), with a P/E of 168.75, indicating significant unprofitability despite explosive prior-year revenue growth of +297063.3%.

SPRY CEO Lowenthal sells 100,000 shares for $1,167,100.00 as stock down -35.3% from 52-week high amid -97.7% revenue decline

Richard E. Lowenthal, President and CEO, executed 2 separate sales totaling 100,000 shares (100.0K shares) for $1,167,100.00 on 2024-12-17 at a blended average price of $11.67, reducing his holdings from 1,198,499 to 1,098,499 shares. The transaction occurs as ARS Pharmaceuticals faces severe fundamental deterioration: annual revenue contracted -97.7% year-over-year to $2,068,000.00 in the latest quarter, the company posted a net loss of $-19,128,000.00 for the full fiscal year, and the stock has declined -35.3% from its 52-week high and -17.9% over the prior 30 days. His same-ticker trading history at SPRY shows a pattern of sales preceding stock declines: recent sales on 2024-12-10 and 2024-11-19 have registered 30-day post-transaction returns of -18.8%, and a sale on 2024-11-12 showed a -28.4% post-transaction 30-day return. While the transaction price of $11.67 exceeds the current price of $11.32, the timing of these sales into a collapsing revenue base and sustained downward price momentum warrants investor attention.

CEO Lowenthal sells 100,000 SPRY shares for $1,316,420.00 as stock falls 29.8% in 30 days

Richard E Lowenthal, President and CEO, executed 2 separate sales totaling 100,000 shares for $1,316,420.00 on 2024-12-10, reducing his holdings from 1,248,499 to 1,148,499 shares. The timing is notable: the stock is down 29.8% from its 52-week high of $17.49 and has declined 29.8% over the past 30 days alone. Company fundamentals show severe deterioration—annual revenue contracted 97.7% to $2,068,000.00 in the latest quarter, net income stands at $-19,128,000.00, and the company remains unprofitable. This sale follows a cluster of 5 prior SPRY sales by the same insider between 2024-11-12 and 2024-11-19, all too recent to measure outcomes. Investors should track whether this sustained selling pattern by the CEO reflects operational distress or portfolio management unrelated to company performance.

ARS Pharma CEO Lowenthal sells 100,000 shares (100.0K shares) for $1,394,960.00 as stock down 20.3% in 30 days amid severe revenue collapse.

Richard E Lowenthal, President and CEO, executed 2 separate sales totaling 100,000 shares at $13.95 on 2024-11-19, raising $1,394,960.00 and reducing his holdings from 1,298,499 to 1,198,499 shares. The sale comes as SPRY has fallen 20.3% over the past 30 days and 23.5% from its 52-week high of $17.49, reflecting deteriorating market sentiment. Company fundamentals are severely distressed: annual revenue growth contracted 97.7%, latest quarterly revenue stands at $2,068,000.00, and the company posted a net loss of $-19,128,000.00 over its most recent full fiscal year, indicating material unprofitability. Lowenthal's cross-ticker track record shows an 85.71% well-timed sell rate (higher = better; sells are well-timed when stock falls after), but his same-ticker history at SPRY shows 0 of 0 prior 90-day measurable sells were well-timed, providing no validation of timing accuracy at this specific ticker. The stock's recent momentum and the company's deteriorating financial trajectory form the immediate context for this transaction.

SPRY CEO Lowenthal sells 100,000 shares for $1.7M across 4 transactions on 2024-11-12; post-transaction holdings 1.25M shares.

Richard E Lowenthal, PRESIDENT AND CEO, filed 4 separate sales totaling 100,000 shares for $1,684,642.45 on 2024-11-12 at blended average price $16.85. The company is unprofitable (net income $-19.1M in latest full year) with annual revenue growth of -97.7%, and current stock price of $14.11 is -19.3% from its 52-week high. Lowenthal's cross-ticker track record shows prior sells have had poor timing outcomes (90d well-timed rate 0.00%), though his same-ticker history at SPRY has been mixed: three October 15 sales showed negative 30-day returns (-5.2%, -7.5%, -5.1%) while two October 8 sales showed positive 30-day returns (+16.7% each). The stock has declined -7.4% over 30 days and -19.3% from peak, suggesting recent market pressure on the company. This sale reduces Lowenthal's holdings by 7.4% to 1.25M shares while the company operates under significant financial headwinds.

CEO Richard E Lowenthal sells 100,000 shares ($1.5M) across 3 transactions on 2024-10-15; holds 1,298,499 shares post-sale.

Richard E Lowenthal, President and CEO of ARS Pharmaceuticals, executed 3 separate sales totaling 100,000 shares for $1,487,595.07 at a blended average price of $14.88 per share on 2024-10-15, reducing his holdings by 7.2%. The company faces significant headwinds: annual revenue growth declined 97.7% year-over-year to $500,000.00 in the latest quarter, while net income deteriorated to $-12,516,000.00, and the company remains unprofitable on a full-year basis. The stock has appreciated 23.6% over the past 30 days and 53.0% over 90 days, trading at $16.13 (2.4% below its 52-week high of $16.52), suggesting Lowenthal sold into recent strength. His cross-ticker historical record shows 20 prior sells with an average 90-day return of +36.6% and a 0.00% well-timed rate, meaning his prior sales have generally been followed by stock appreciation—a pattern of poor timing. At SPRY specifically, his 5 most recent prior trades (all sells) show outcomes ranging from +21.0% to +24.7% over 30 days where measurable, indicating he has consistently sold before further gains. This filing provides no explicit indication of scheduled/plan-based trading and warrants examination of whether the magnitude and timing of this sale—amid steep operational decline and recent price momentum—reflects a strategic capital event or other material development.

CEO Richard E Lowenthal sells 100,000 shares ($1.4M) at $13.83 as SPRY near 52-week high

Richard E Lowenthal, President and CEO of ARS Pharmaceuticals, executed 2 separate sales totaling 100,000 shares for $1,382,775.00 at $13.83 per share on 2024-10-08, reducing his holdings from 1,448,499 shares to 1,348,499 shares (a -6.9% reduction). The sale occurred near the company's 52-week high of $14.89, with the current price at $13.91 representing -6.6% from that peak. While SPRY has appreciated +20.8% over the past 30 days and +22.6% over 90 days, the company faces significant operational headwinds: revenue collapsed -97.7% on a year-over-year basis, with the latest quarter showing only $500,000.00 in revenue against net losses of $-12,516,000.00. Lowenthal's cross-ticker track record shows 20 prior sells with a 0.00% well-timed rate (90-day returns after prior sells averaged +6.7%, meaning those sales were typically followed by further gains), and his SPRY-specific sales pattern from August through September shows mixed near-term performance (one trade down -4.9% at 30 days, others up +21.0%). The divergence between positive price momentum and deteriorating fundamentals merits investor attention.

SPRY CEO Lowenthal sells 100,000 shares at $12.93 for $1,293,205.00; holds 1,398,499 post-transaction

Richard E. Lowenthal, President and CEO of ARS Pharmaceuticals, executed 2 separate sales totaling 100,000 shares for $1,293,205.00 on 2024-09-17 at $12.93 per share, reducing his holdings by 6.7% to 1,398,499 shares. The transaction occurred near the company's 52-week high of $14.89 (current price $14.86, -0.2% from peak), following strong 90-day momentum of +81.9%. However, the company faces substantial headwinds: annual revenue declined 97.7% to $500,000.00 in the latest quarter, net income was -$12,516,000.00, and the company remains unprofitable. Lowenthal's prior SPRY trades from August-September show negative 30-day returns (-8.6%, -4.8%, -4.9%), though measurable 90-day outcomes remain incomplete for recent transactions.

SPRY CEO Lowenthal sells 100,000 shares at $11.50 on 2024-09-10 for $1.1M; stock up +45.8% in 90 days but revenue collapsed -97.7% YoY.

CEO Richard E Lowenthal executed 2 separate sales totaling 100,000 shares for $1,149,775.00 at $11.50 on 2024-09-10, reducing his holdings by 6.5% from 1,548,499 to 1,448,499 shares. The sale occurs despite strong recent momentum: the stock has rallied +45.8% over the prior 90 days and is trading at $12.63, a 10% premium to the transaction price. However, the timing is noteworthy against deteriorating fundamentals—annual revenue contracted -97.7% (latest quarter revenue of $500,000.00 against prior full-year baseline), and the company reported a net loss of $-12,516,000.00 for its most recent full fiscal year. Lowenthal's cross-ticker track record shows a 0.00% well-timed rate on his 20 prior open-market sells, indicating his historical sell signals have not preceded subsequent declines. This sale represents a discretionary reduction of CEO holdings into a rallying market against the backdrop of severe revenue deterioration.

SPRY CEO Richard E Lowenthal sells 100,000 shares in 6 transactions for $1.5M on 2024-08-20

CEO Richard E Lowenthal executed 6 separate sales totaling 100,000 shares (100.0K shares) for $1,502,586.53 ($1.5M) across three price levels on 2024-08-20, reducing his holdings from 1,598,499 shares (1.60M shares) to 1,498,499 shares (1.50M shares), a -6.3% reduction. The company's financial position is stressed: latest quarterly revenue was $500,000.00 ($500.0K), annual revenue growth contracted -97.7%, and full-year net income was negative at $-12,516,000.00 ($-12.5M), indicating material operational challenges. The timing of this large CEO sale, coupled with the company's severe revenue decline and unprofitable state, occurs against a backdrop where Lowenthal's cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 25.00%, and his same-ticker history at SPRY includes 4 additional sells just 7 days prior on 2024-08-13 that remain outcome-unmeasurable.